Dimence
Deventer, Netherlands
Location status: Recruiting
Location contact
Dominique Jonkers, Master
CONTACT
Maarten K van Dijk, PhD
CONTACT
NCT Number: NCT06279598
The aim of this study is to increase understanding of the effectiveness and efficiency of psychological treatment for adult patients with posttraumatic stress disorder -PTSD- and to make it more personalized.
Key questions:
1. Which predictors of treatment success influence treatment outcome of patients with PTSD who receive the three psychotherapeutic treatments investigated in this study? 2. Which specific moderators can be identified with regard to the different psychotherapies (Eye Movement Desensitization and Reprocessing -EMDR-; Prolonged Exposure -PE-; and Interpersonal Psychotherapy -IPT- in the second phase)? 3. In patients with PTSD, does offering another proven effective form of trauma-focused psychotherapy (PE after EMDR, or EMDR after PE) improve symptoms following insufficient response to a first trauma-focused treatment? 4. Is switching from a trauma-focused therapy to a non-trauma-focused treatment (IPT) a more effective strategy for dealing with non-response to a first proven effective psychotherapeutic treatment compared to switching to another trauma-focused therapy? 5. Are there differences in treatment tolerance and differences in dropout rates between PE, EMDR and IPT?
Secondary goals:
* Investigating the extent to which therapist allegiance to a specific therapy method affects outcomes; * Investigating whether the quality of therapy implementation or the treatment integrity ('adherence/ competence') affects treatment outcomes; * Investigating how much the quality of the therapeutic alliance influences outcomes.
Participants receive treatment and will complete questionnaires. The study is conducted in two phases. Its aim is to compare two different trauma-focused treatments (EMDR and PE) for patients with PTSD to one another and with a nontrauma-focused psychotherapy (IPT) and to investigate possible predictors and moderators for treatment success. Patients will first be randomized to PE or EMDR in the first treatment phase. After this first phase, non-responders are re-randomized for a second phase of treatment. They receive either the alternative phase 1 trauma-focused psychotherapy or IPT as non-trauma-focused therapy. In phase 1 researchers will compare the PE and EMDR group to see which treatment is most effective for whom. In phase 2 researchers will compare the trauma-focused treatments (PE and EMDR group) with the nontrauma-focused treatment (IPT group) to see which treatment is most effective for whom.
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Not applicable
Deventer, Netherlands
Location status: Recruiting
Dominique Jonkers, Master
CONTACT
Maarten K van Dijk, PhD
CONTACT
Background of the study:
The symptoms of posttraumatic stress disorder (PTSD) follow exposure to a traumatic event and are accompanied by significant functional limitations. PTSD is very common: a multinational study shows a lifetime prevalence of 3.9%. Effective treatment options exist for people with PTSD, with Eye Movement Desensitization and Reprocessing (EMDR) and Prolonged Exposure (PE; a specific form of trauma-focused Cognitive Behavioral Therapy, T-CBT) both listed as first-choice interventions in the Dutch standard of care for psychotrauma and stressor related disorders. About 40% of patients with PTSD do not benefit sufficiently from either of the aforementioned guideline treatments and about 18% of patients do not complete a trauma-focused treatment (treatment dropout). Knowledge about general predictors of treatment success in psychotherapy is limited, making it currently impossible to predict which patient will or will not benefit from which specific psychotherapeutic treatment (i.e., EMDR vs. PE). Little scientific knowledge exists about optimal follow-up treatment when patients insufficiently benefit from their initial treatment. For patients who drop out (e.g. from inability to tolerate exposure to traumatic memories) or do not benefit from exposure therapies, an alternative is to switch not to another proven effective trauma-focused intervention, but to a non-trauma-focused intervention. A suitable non-traumafocused treatment is Interpersonal Psychotherapy. Previous research suggests that IPT can be an effective first-line treatment option, but the effectiveness of IPT as a second treatment step for people with PTSD who have not responded to a trauma-focused psychotherapy has never been investigated. We hypothesize that IPT will yield greater symptom reduction and less dropout for patients with PTSD who do not respond to a course of trauma-focused psychotherapy compared to switching to another trauma-focused therapy.
Study population:
Subjects are recruited from Dimence, a mental health institution in the Netherlands. Subjects are recruited from patients who register for outpatient treatment within the Dimence division "Specialistic Diagnostics and Treatment" with a primary diagnosis of PTSD. It concerns adults between 18 and 65 years old, both men and women.
Intervention:
Half of initially non-responsive patients will be treated with the non-trauma-focused intervention interpersonal therapy (IPT) in phase 2 of the study. The first and second phases will offer the trauma-focused treatments Prolonged Exposure and EMDR.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness (if applicable):
Major adverse events are not expected as these have not been documented in previous studies. The greatest burden on subjects is completing the questionnaires necessary to answer the primary research questions. In phase 1, this totals approximately 10.5 hours (with baseline measurement the most extensive and subsequent weekly measurements); for patients treated for an additional 8 weeks in phase 2, completing the questionnaires takes approximately another 6 hours. A patient participating in both treatment phases therefore spends a total of approximately 16.5 hours completing assessments. The prescription of patients taking medication must be stable prior to the study, and then not changed during the study, unless necessary due to a crisis or serious side effects. Patients receive treatment sessions twice a week, which is relatively frequent compared to usual treatment, but research shows that dropout is lower with two weekly sessions. Study participation further assures patients that the treatments they receive are performed as intended by the therapy-developer because therapists receive supervision and checks are made to ensure treatment integrity.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This concerns a form of psychotherapy for PTSD.
Other names: Trauma-focused CBT
This concerns a form of psychotherapy for PTSD.
This concerns a form of psychotherapy for PTSD.
Time frame: Measured every week for 8 weeks in phase 1 and measured every week of 8 weeks in phase 2 of the study.
The primary outcome measure for the effectiveness of the treatment in both phases is symptom reduction (less burden of PTSD symptoms) measured with the PTSD checklist for the DSM-5 (PCL-5). The Dutch version of the PCL-5 will be used, the PCL-5 is administered at baseline and repeated weekly. The PCL-5 is a self-report questionnaire of 20 items about the DSM-5 symptoms of PTSD. This measure will be used to monitor symptom change during and after treatment in both phases of the study.
Time frame: Measured at baseline, at the end of treatment in phase 1 (= after 8 weeks) and at the end of the treatment in phase 2 (= after 16 weeks = end of the study).
The Dutch version of the CAPS-5 will be used as it is "the gold standard" in PTSD assessment. The CAPS-5 is a 30-item structured clinical interview that we will use, among other things, to determine the current (past month) diagnosis of PTSD and to assess improvement in symptoms since a previous CAPS administration.
Time frame: Measured at baseline, at the end of treatment in phase 1 (= after 8 weeks) and at the end of the treatment in phase 2 (= after 16 weeks = end of the study).
The Dutch version of the ITQ will be used: "Internationale Trauma Vragenlijst" (ITV). The International Trauma Questionnaire (ITQ) is a self-report questionnaire consisting of 18 items that measures complex PTSD (C-PTSD) symptoms according to the diagnostic criteria of the 11th revision of the International Classification of Diseases (ICD-11; World Health Organization).
Time frame: Measured every week for 8 weeks in phase 1 and measured every week of 8 weeks in phase 2 of the study.
The Dutch version of the HADS will be used. The Hospital Anxiety and Depression Scale is a 14-item self-report questionnaire and can be used to measure levels of anxiety and depression.
Time frame: Measured at baseline, at the end of treatment in phase 1 (= after 8 weeks) and at the end of the treatment in phase 2 (= after 16 weeks = end of the study).
The Dutch version of the MHC-SF will be used: the Dutch short-form Mental Health Continuum. The MHC-SF comprises 40 items that measure emotional well-being, psychological well-being and social well-being.
Time frame: Measured at baseline, at the end of treatment in phase 1 (= after 8 weeks) and at the end of the treatment in phase 2 (= after 16 weeks = end of the study).
The Dutch version of the self-report questionnaire Positive and Negative Effects of Psychological Treatment (PNEP) will be used to assess both positive and possibly unfavorable and adverse events in psychological treatments. The Dutch questionnaire consists of 3 questions and 71 items.
Time frame: Measured at baseline.
We are investigating generic predictors of treatment success and specific moderators based on the scientific literature. Further, we have added several instruments to match those that Wibbelink et al. (2021) use in their research in order to be able to collaborate in future data analyses (PAI analysis).
The first demographic variable is age.
Time frame: Measured at baseline.
We ask about gender.
Time frame: Measured at baseline.
We ask about the level of education.
Time frame: Measured at baseline.
We ask about employment status.
Time frame: Measured at baseline.
We ask about marital status.
Time frame: Measured at baseline.
We ask about ethnicity/race.
Time frame: Measured at baseline.
We ask about medication use.
Time frame: Measured at baseline.
We ask about treatment history.
Time frame: Measured at baseline.
The Mini-Schedules for Clinical Assessment in Neuropsychiatry is a shortened version of the SCAN 2.1 developed by the World Health Organization (WHO). The Mini-SCAN is a semi-structured diagnostic interview that determines the most common DSM-5 (formerly DSM-IV Axis I) diagnoses using a diagnostic algorithm. The instrument is administered at baseline in the study to determine comorbidity of other disorders with PTSD, including depression, anxiety, and substance use disorders.
Time frame: Measured at baseline.
The Life Events Checklist for DSM-5 (LEC-5) is often used as a standard lead-in to the CAPS-5 to determine Criterion A validity. The LEC-5 comprises 17 items.
Time frame: Measured at baseline.
The Childhood Trauma Questionnaire-Short Form (CTQ-SF) will be administered at baseline to assess the severity of five types of child abuse: emotional abuse, physical abuse, sexual abuse, emotional neglect and physical neglect. The CTQ-SF consists of 28 items.
Time frame: Measured at baseline and at the end of treatment in phase 1 (= after 8 weeks).
The "Hostility" subscale of the Symptom Checklist-90-Revised (SCL-90-R) will be used to measure anger. This subscale of the SCL-90-R consists of 6 items rated on a 5-point Likert scale ranging from 0 ('not at all') to 4 ('extremely') and assesses anger-related thoughts, feelings, and actions.
Time frame: Measured at baseline and at the end of treatment in phase 1 (= after 8 weeks).
General attachment style will be measured using the Experiences in Close Relationships-Relationship Structures questionnaire (ECR-RS). The ECR-RS comprises 9 items rated on a 7-point Likert scale ranging from 1 ('completely disagree') to 7 ('completely agree). The ECR-RS measures attachment-related avoidance and attachment-related anxiety.
Time frame: Measured at baseline and at the end of treatment in phase 1 (= after 8 weeks).
The Brief Experiential Avoidance Questionnaire (BEAQ) will be used to measure experiential avoidance. The BEAQ measures six different domains: behavioral avoidance, fear aversion, suppression, procrastination, repression/denial and distress endurance. The BEAQ comprises 15 items rated on a 6-point Likert scale from 1 ('strongly disagree') to 6 ('totally agree').
Time frame: Measured at baseline and at the end of treatment in phase 1 (= after 8 weeks).
Social problems (including housing problems, unemployment, social isolation) will be assessed with a list of social problems derived from the Improving Access to Psychological Therapies (IAPT) program.
Time frame: Measured at baseline and at the end of treatment in phase 1 (= after 8 weeks).
The Posttraumatic Cognitions Inventory (PTCI) is a questionnaire consisting of 33 items that assess trauma-related cognitions measured in three domains: negative cognitions about oneself, negative cognitions about the world, and self-blame.
Time frame: Measured at baseline and at the end of treatment in phase 1 (= after 8 weeks).
The Trauma Related Guilt Inventory (TRGI) will be administered to measure feelings of guilt related to the trauma. The questionnaire consists of 32 items rated on a 5-point Likert scale.
Time frame: Measured at baseline and at the end of treatment in phase 1 (= after 8 weeks).
A Dutch translation of the Trauma Related Shame Inventory (TRSI) will be administered to measure shame. Shame is defined in the TRSI as a negative and painful self-evaluation in the traumatic context and a tendency to withdraw and hide from others. The questionnaire comprises 24 items rated on a 4-point Likert scale from 1 ('not true for me') to 4 ('completely true for me').
Time frame: Measured every week for 8 weeks in phase 1 and measured every week of 8 weeks in phase 2 of the study.
The therapeutic relationship will be measured with the Working Alliance Questionnaire - shortened version (WAV-12). The WAV-12 is derived from the WAV-36, the Dutch translation from the Working Alliance Inventory (WAI). The questionnaire measures the bond between patient and therapist, agreement on the goals of treatment and agreement on the tasks in therapy. The WAV-12 consists of 12 items rated on a 5-point Likert scale from 1 ('rarely or never') to 5 ('always').
Time frame: Measured at baseline.
An 'expectancy rating' will be used to assess the expectations of patiens and practitioners of the treatment methods offered in the study (Prolonged Exposure, EMDR and IPT).This expectancy rating is administered at baseline and comprises 3 items (one about Prolonged Exposure, one about EMDR and one about IPT) in which patients and practitioners assess the expectation that the therapy will help the patient on scale from 0 ('not at all') to 100 ('maximum').
Contact information is provided by the study sponsor or research team.
Dominique Jonkers, Master
CONTACT
Maarten K van Dijk, PhD
CONTACT
University of Groningen
Other
PT-STRESS Study: A Two-phase RCT Aimed at Predicting Treatment Success and Dealing With Non-response in the Treatment of PTSD; by Alternating Between Two Trauma-focused Treatments (EMDR/PE) or by Switching to Interpersonal Therapy (IPT)
Acronym: PT-STRESS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06770998
Mental Disorders, Stress Disorders, Post-Traumatic
Birmingham, Alabama, United States
View Trial DetailsNCT07656545
Acute Stress Disorder, Burns
Los Angeles, California, United States
View Trial DetailsNCT04605198
Behavior, Behavioral Symptoms
Escondido, California, United States
View Trial DetailsNCT03485391
Anxiety Disorders, Mental Disorder
Charleston, South Carolina, United States
View Trial Details